2017 American Transplant Congress
Does Blockade of ICOS/ICOS-L Pathway Act Synergistically with αCD40 Costimulation Pathway Blockade?
University of Maryland School of Medicine, Baltimore, MD
Purpose: Inducible costimulator (ICOS) on T cells enhances basic T cell responses to foreign antigen, and increased ICOS expression is detected in association with pathogenic…2017 American Transplant Congress
Effect of Everolimus-Based Regimen on Graft Outcomes in Kidney Transplant Recipients with Diabetes at Baseline: Post-Hoc Analysis from the ELEVATE Study.
1ELEVATE Study Group, Leiden, Netherlands; 2Novartis Pharma AG, Basel, Switzerland
Purpose: Presence of diabetes may have adverse impact on graft outcome in kidney transplant recipients (KTxRs). This post-hoc analysis from the ELEVATE study compared the…2017 American Transplant Congress
The Efficacy and Safety of Plaquenil in Kidney Transplants Patients with Lupus.
Background: Hydroxychloroquine, also known as Plaquenil ( PLQ) is an antimalarial drug with immunomodulatory action. Recent studies have demonstrated a protective effect of PLQ in…2017 American Transplant Congress
Outcomes and Risk Factors for Graft Loss: Lessons Learned from More Than 1,056 Pediatric Kidney tx at a Single Center.
Aim:To study outcomes and risk factors for graft loss in > 1056 pediatric renal tx.Methods:We studied outcomes by immunosuppression era: I) 1963-83 (ALG, AZA and…2017 American Transplant Congress
Effect of Everolimus-Based Immunosuppressive Regimen on New Onset of Diabetes After Kidney Transplantation – A 24 Month Subanalysis from the ELEVATE Study.
1ELEVATE Study Group, Oslo, Norway; 2Novartis Pharma AG, Basel, Switzerland
Purpose: New onset diabetes after transplantation (NODAT) is a common metabolic complication which affects long-term patient survival and graft outcomes. Most of the immunosuppressive drugs…2017 American Transplant Congress
Evolution of Lipid Profile and Major Adverse Cardiac Events in Kidney Transplant Recipients Converted from Calcineurin Inhibitor to Everolimus: 24-Month Subanalysis from Elevate Study.
1ELEVATE Study Group, Berlin, Germany; 2Novartis Pharma AG, Basel, Switzerland
PURPOSE: Posttransplant (post-Tx) lipid abnormalities may increase risk of cardiovascular (CV) events in kidney transplant recipients (KTxR). Previous analysis from ELEVATE (NCT01114529) study confirmed that…2017 American Transplant Congress
A Phase-Two, Randomised, Placebo-Controlled Trial: Belimumab in Renal Transplantation Targets Naïve, Activated Memory and Antibody Producing B Cells Whilst Sparing Regulatory B Cells.
This phase 2, double-blind, randomised controlled study (BEL114424) explores the safety and potential efficacy of addition of belimumab to standard of care in renal transplantation…2017 American Transplant Congress
Tacrolimus Suppresses Calcineurin Activity and Ca2+ Influx Age-Specifically.
Immunosenescence is impacting alloimmunity and outcomes after organ transplantation. Age-dependent effects of immunosuppressants, however, have not been tested sufficiently. Here, we tested the effects of…2017 American Transplant Congress
Tofacitinib-Loaded Solid Lipid Nanoparticles Inhibits Dendritic Cell Antigen Presenting Functions and Achieve Selective In Vivo Targeting.
BackgroundComplications from long-term use of calcineurin inhibitors are a major concern for transplant patients. To develop CNI-free therapies, we investigated an innovative drug delivery method…2017 American Transplant Congress
Infections and Outcomes in Renal Transplantation Patients Using Alemtuzumab for Induction Immunosuppression: Preliminary Results.
Surgery, University of Toledo College of Medicine, Toledo, OH
Introduction: Alemtuzumab (Ale) is a monoclonal antibody targeting CD52+ lympocytes. We sought to determine the impact of Ale immunodepletion, with steroid freedom for low risk…
- « Previous Page
- 1
- …
- 93
- 94
- 95
- 96
- 97
- …
- 138
- Next Page »